Licensing Packaging Pharma Companies Vaccine 
pharmaphorum
OCTOBER 7, 2021
Moderna has said it plans to invest $500 million in a new facility for manufacturing mRNA vaccines in Africa, and has kicked off a search to find a suitable country and location. of Africans have been fully vaccinated against COVID-19, and just 15 African nations have met the agency’s objective of 10% coverage.
pharmaphorum
JUNE 11, 2021
Ocugen is the first company to be affected by the FDA’s recent decision to raise the bar on emergency use authorisations for COVID-19 medicines, and will have to file for full approval of its vaccine candidate. The Russian Sputnik V vaccine was approved for use in India in April. That includes the more transmissible B.1.617.2
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
APRIL 12, 2021
A blood-thinning agent, heparin, had been adulterated due to the product license holder (Baxter) procuring a toxic substance that had been illegally substituted for the genuine registered material. Can patients really be confident in pharma supply chains? Why would a pharma company take risks like these?
pharmaphorum
MAY 27, 2022
There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials. Underrepresentation is multifactorial, so concerted efforts from life science companies are required to address inequitable healthcare. What comes next? About the interviewees.
Drug Discovery World
MARCH 29, 2023
The commission is looking to put more pressure on pharma companies to report such shortages, and to offer a drug’s marketing authorisation to another company before withdrawing it from the market. This looks like it may change shape in the future for the region, if the proposal put forward by the commission is adopted.
pharmaphorum
MAY 26, 2022
While many pharma companies are actively working on initiatives to improve diversity in clinical trials, we still have a long way to go. A risk-benefit approach underpins the decision-making process to evaluate human drugs, drug/device combinations and advanced therapy medicinal products for licensing of human medicines.
Drug Discovery World
AUGUST 5, 2022
One indirect effect of the Covid pandemic – and the successful development of numerous vaccines at unprecedented speed – has been a greater-than-ever demand for new, effective medicines to be developed more quickly and efficiently, without compromising on safety. Why sponsors use external consultants.
Expert insights. Personalized for you.
93 
Let's personalize your content